Considerations Regarding Food And Drug Administration Review and Regulation of Drugs for the Treatment of Amyotrophic Lateral Sclerosis; Public Hearing

 
Docket ID: FDA-2013-N-0035
Agency: Food and Drug Administration (FDA)
Parent Agency: Department of Health and Human Services (HHS)
Docket Details open glossary dialog  
Related RINs: None
Related Dockets: None
Short Title: Considerations Regarding Food And Drug Administration Review and Regulation of Drugs for the Treatment of Amyotrophic Lateral Sclerosis; Public Hearing
Keyword(s): Public Hearing, Amyotrophic Lateral Sclerosis, Review and Regulation , CDER201219
Type: Nonrulemaking
Center: CDER
Docket Item Code: N
 

Primary Documents

View All  (3)
Comment Period Closed
Mar 25, 2013 11:59 PM ET
Notice
Posted: 01/31/2013
ID: FDA-2013-N-0035-0001
Comment Period Closed
Other
Posted: 09/11/2014
ID: FDA-2013-N-0035-0272
Comment Period Closed
Other
Posted: 04/19/2013
ID: FDA-2013-N-0035-0271

Supporting Documents

 
No documents available.

Comments

View All  (269)

778
Comments Received*
*This count refers to the total comment/submissions received on this docket, as of 11:59 PM yesterday. Note: Agencies review all submissions, however some agencies may choose to redact, or withhold, certain submissions (or portions thereof) such as those containing private or proprietary information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign. This can result in discrepancies between this count and those displayed when conducting searches on the Public Submission document type. For specific information about an agency’s public submission policy, refer to its website or the Federal Register document.